Aurora Kinase Inhibitor III

• CAT Number: R067031
• CAS Number: 879127-16-9
• Molecular Formula: C21H18F3N5O
• Molecular Weight: 413.40
• Purity: ≥95%
• Synonyms: C-1368;INH 1
• Target: Epigenetics
• Storage: 2-8°C
• IUPAC Name: N-[3-[[4-[3-(trifluoromethyl)anilino]pyrimidin-2-yl]amino]phenyl]cyclopropanecarboxamide
• InChI: InChI=1S/C21H18F3N5O/c22-21(23,24)14-3-1-4-15(11-14)26-18-9-10-25-20(29-18)28-17-6-2-5-16(12-17)27-19(30)13-7-8-13/h1-6,9-13H,7-8H2,(H,27,30)(H2,25,26,28,29)
• InChIKey: RDTDWGQDFJPTPD-UHFFFAOYSA-N
• SMILES: C1CC1C(=O)NC2=CC=CC(=C2)NC3=NC=CC(=N3)NC4=CC=CC(=C4)C(F)(F)F

Aurora Kinase Inhibitor III（Cat No.:R067031）is a selective inhibitor targeting Aurora kinases, a family of serine/threonine kinases crucial for regulating cell division and mitotic processes. By inhibiting these kinases, Aurora Kinase Inhibitor III disrupts mitotic spindle formation and induces apoptosis in cancer cells, making it a promising candidate for cancer therapy. Preclinical studies have shown efficacy against various tumor types, including solid tumors and hematological malignancies. Ongoing research focuses on its pharmacokinetics, safety profile, and potential applications in combination with other cancer treatments to enhance therapeutic outcomes in oncology.